Legal considerations of pricing in the pharmaceutical industry in Iran and selected countries
Subject Areas : Recent Developments in public law
shahryar eslamitabar
1
(Faculty of Smart Medical Sciences University)
ehsan lame
2
(Master of International Trade Law)
fateme anvar
3
(Master of Private Law)
Keywords:
Abstract :
Economic access to medicine and treatment is one of the most important aspects of the right to health, and the realization of it requires that every government pursue specific strategies according to the conditions:riorities and needs of its public health. Due to the variability of exchange rates and sanctions, the importance of these issues in Iran is more than other countries. Since Iran has recently abandoned the Cost Plus method, after determining the price, it is necessary to always adjust the prices according to the current conditions and needs and the existence of similar drugs, but this measure is not normal in the case of single prescription drugs. Necessary and sufficient considerations have not been considered. While developed countries such as France and the United Kingdom insure all drugs on the list without special requirements and prerequisites, the budgets of countries such as Iran do not allow this, so it seems The issue of budget shortages is expected to be overshadowed by many policies, including the drug economy and price regulation. On the other hand, although the price correction is done annually due to price changes in the reference and importing country.
_|1 .نامی پارسا، نگار، 1393،)تأمین دارو حقوق و تکالیم دولت ها در نظام بین الملل، موسسه مطالعات و
پژوهشهای شهر دانش، چاپ اول
ب: مقاالت
2.ویانچی، امیر و سایرین)1394« .)بررسی پوشش بیمه دارو در ایران در مقایسه بها کشهورهای
منتخب«. مدیریت سالمت، 180( 60)
3.دلگشایی، بهرام. و سایرین)1384« .)مقایسه نظام قیمهت گهذار ی و بیمهه دارو در ایه ران و کشهورها ی
منتخب«. فصلنامه علمی- پژوهشی مدیریت سالمت، دوره 8 ،شماره 22 ،زمستان 1384
2 .انگلیسی
A: Books
4.M.N.G. Dukes(2006), The Law and Ethics of the Pharmaceutical Industry,
Elsevier Science
5. John Rapoport and Others. "Cost containment and Efficiency in National Health
Systems: A Global Competition. Wiley Blackwell", 2009;
B:Aticles
6. Alistair McGuire & Others.(2008) "Pricing Pharmaceuticals: Value Based Pricing
in What Sense?" Pharmaceutical Policy, Eurohealth, Vol. 14, No 2
7.Delgoshaie,b, Turani, sogand(2009)"Comparative Study of Pricing &
Reimbursement Indexes of Pharmaceuticals in Iran & Selected Countries": Legal
Approach, Department of Health & Social Care. "Proposed Changes to the Statutory
Scheme to control the Cost of Branded Health Service Medicines".
8.Dimitra Panteli & Others(2016). "Health System in Transition". Vol. 18, No. 5.
Pharmaceutical ---Regulation in 15 European Countries. Review. European
9.Emil Aho & Others(2017). "International Price Comparison of Pharmaceuticals".
TLV: the Dental and Pharmaceutical Benefits Agency, Feb 2018:P 84-85.
9.John Rapopor & others(2009). "Cost Containment & Efficiency in national Health
System". Wiley Blackwell,
10. Tuan anh Nguyen and others(2016) .Policy options for Pharmaceutical Pricing
and Purchasing: issues for Low and middle – income countries. Oxford university
Press, Health policy and planning 2015; 30:267-280.
11.Monique F. Mrazek.(2002) "Comparative Approaches to Pharmaceutical Price
Regulation in the European Union". CMJ: Croatian Medical Journal. 43(4):453-
461,
12.Steven Morgan(2015). "Summaries of National Drug Coverage and
Pharmaceutical Pricing Policies in 10 Countries": Working Paper for the 2016
Meeting of the Vancouver Group in New York, NY.
13.Leo Ewbank & Others. The Rising Cost of Medicines to the NHS. What's the
Story? The King's Fund, April 2018; P 2.
14. Emil Aho & Others(2017). "International Price Comparison of Pharmaceuticals"
2017. TLV: the Dental and Pharmaceutical Benefits Agency, Feb 2018: 90.
فصلنامه دستاوردهای نوین در حقوق عمومی، سال اول،شماره سوم،پاییز1401
21
15.House of Parliament: parliamentary Office of Science and Technology. Drug
Pricing. Potstone, No 364, Oct 2010.
16. S & B (Stevens & Bolton LLP) . Spotlight on Pharmaceutical Pricing
Regulation: The UK Pharmaceutical Pricing Landscape.
17.NHS. "Question and Answer Document for the NHS on the Pharmaceutical
Price Regulation Scheme" (PPRS). Publication Gateway Reference 01604; P 3.
19. "Observatory on Health System and Policies": a partnership hosted by WHO.
20. Hashemi- Meshkini Amir & Others. Pharmacist Remuneration Models in Iran
and Selected Countries: A Comparative Study. Iranian Journal of Pharmaceutical
Research, (2013), 12(4): 955-964.
21.Ronald J. Vogel. "Pharmaceutical Economics and Public Policy". Haworth Press,
Inc. 2007. P
22.Panos Kanavos & Others. "The Impact of External Reference Pricing within and
across Counties". LSE, 2017;
23. Monique F. Mrazek." Comparative Approaches to Pharmaceutical Price
Regulation in the European Union. CMJ": Croatian Medical Journal. 43(4):453-
461, 2002. P 459.
24.Abbas Kebriaee-Zadeh. "Overview of National Drug Policy of Iran". Iranian
Journal of Pharmaceutical Research, 2003; I-II.
25. Mehdi Varmaghan & Others(2016). "An Overview to Pharmaceutical Financing
in Iran". Journal of Pharmaeconomics and Pharmaceutical management; 2 (1-2):
45-9.
26.WHO & Hai Global. "Medicine Prices, Availability, Affordability and Price
Components": Islamic Republic of Iran,
27. Tuan Anh Nguyen & Others. "Policy Options for Pharmaceutical Pricing and
Purchasing": Issues for Law- and Middle-Income countries. Oxford University
Press. Health Policy and Planning 2015;
29 Mehdi Varmaghani & Others. "An Overview to Pharmaceutical Financing in
Iran". --Journal of Pharmaeconomics and Pharmaceutical management. 2016; 2 (1-
2): 45-9: 47.
30.Hamid Reza Jamshidi & Others(2014). "Budget Impact Analyses: A Practical
Policy Making Tool for Drug Reimbursement Decisions". Iranian Journal of
Pharmaceutical Research 13(3):1105-1109.|_
